HANATOUR JAPAN CO.,LTD. Logo

HANATOUR JAPAN CO.,LTD.

B2C/B2B travel firm providing packages, MICE, and inbound services, with a focus on Korea.

6561 | T

Overview

Corporate Details

ISIN(s):
JP3769900006
LEI:
Country:
Japan
Address:
港区虎ノ門五丁目12番1号
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

HANATOUR JAPAN CO.,LTD. is an integrated travel company that provides a wide range of domestic and international travel services. The company operates in both business-to-consumer (B2C) and business-to-business (B2B) markets. Its core offerings include the design and execution of diverse travel packages, hotel booking, and ticketing. HANATOUR JAPAN specializes in various segments, including leisure holidays, educational tours, and corporate incentive travel, with a particular focus on Meetings, Incentives, Conferences, and Exhibitions (MICE). A key area of its business is managing inbound travel services, especially from South Korea. For its B2B partners, the company provides travel business solutions to help travel agents customize tours and enhance sales.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 09:01
Interim Report
確認書
Japanese 9.2 KB
2025-08-14 09:00
Interim Report
半期報告書-第21期(2025/01/01-2025/12/31)
Japanese 225.1 KB
2025-03-31 06:22
Regulatory News Service
臨時報告書
Japanese 26.9 KB
2025-03-28 08:03
Governance Information
内部統制報告書-第20期(2024/01/01-2024/12/31)
Japanese 23.6 KB
2025-03-28 08:03
Registration Form
確認書
Japanese 8.8 KB
2025-03-28 08:02
Registration Form
有価証券報告書-第20期(2024/01/01-2024/12/31)
Japanese 1.0 MB
2024-08-14 09:32
Regulatory News Service
確認書
Japanese 8.9 KB
2024-08-14 09:31
Interim Report
半期報告書-第20期(2024/01/01-2024/12/31)
Japanese 215.0 KB
2024-05-14 09:07
Regulatory News Service
確認書
Japanese 8.9 KB
2024-05-14 09:06
Quarterly Report
四半期報告書-第20期第1四半期(2024/01/01-2024/03/31)
Japanese 182.2 KB
2024-03-29 03:31
Post-Annual General Meeting Information
臨時報告書
Japanese 21.1 KB
2024-03-28 08:04
Regulatory News Service
確認書
Japanese 9.0 KB
2024-03-28 08:03
Regulatory News Service
内部統制報告書-第19期(2023/01/01-2023/12/31)
Japanese 24.0 KB
2024-03-28 08:01
Annual Report
有価証券報告書-第19期(2023/01/01-2023/12/31)
Japanese 1.0 MB
2023-11-14 08:04
Report Publication Announcement
確認書
Japanese 8.9 KB

Automate Your Workflow. Get a real-time feed of all HANATOUR JAPAN CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for HANATOUR JAPAN CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for HANATOUR JAPAN CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Mendus Logo
Developing immunotherapies using dendritic cells to prevent cancer recurrence and improve survival.
Sweden IMMU
Develops AI-driven, glasses-free 3D holographic displays for the defense sector.
United States of America N/A
MicroAd,Inc. Logo
Data-driven marketing tech providing DSP and SSP solutions for digital advertising.
Japan 9553
Microwave Chemical Co., Ltd. Logo
Innovating chemical and metal processing with an eco-friendly microwave platform.
Japan 9227
A think tank providing research, consulting, and ICT solutions to public & private sectors.
Japan 3636
Modalis Therapeutics Corporation Logo
Develops epigenome editing therapies for genetic muscular, heart, and CNS disorders.
Japan 4883
Model Solution Co., Ltd. Logo
One-stop prototyping & low-volume production for IT, electronics, and medical hardware.
South Korea 417970
Modus Therapeutics Holding AB Logo
Developing sevuparin, a polysaccharide for sepsis, septic shock, and chronic inflammation.
Sweden MODTX
Molecure S.A. Logo
Develops first-in-class small molecule drugs for oncology and inflammatory/fibrotic diseases.
Poland MOC
Mural Oncology PLC Logo
Clinical-stage company developing cytokine immunotherapies for hard-to-treat solid tumors.
Ireland MURA

Talk to a Data Expert

Have a question? We'll get back to you promptly.